Table 3

Site-specific cancer incidence by treatment group (through February 1, 1996)

CancerCasesUnadjustedaAdjustedb
SePlaceboRR95% CIPHR95% CIP
All sites1051370.750.58–0.980.030.750.58–0.970.03
Prostate22420.510.29–0.870.0090.480.28–0.800.005
Lung25350.700.40–1.210.180.740.44–1.240.26
Colorectal9190.460.19–1.080.0550.460.21–1.020.057
Other carcinomas690.660.19–2.070.440.670.24–1.880.44
Other noncarcinomas350.590.09–3.040.500.590.14–2.470.47
Esophageal250.390.04–2.410.280.400.08–2.070.28
Melanoma1191.210.46–3.300.681.180.49–2.850.71
Bladder1081.240.44–3.610.661.280.50–3.250.60
Breast1161.820.62–6.010.241.890.69–5.140.21
Head and neck971.270.42–4.010.651.270.47–3.420.63
Lymphoma and leukemia861.320.40–4.610.621.250.43–3.610.68
Cancer mortality, all sites40660.590.39–0.890.0080.590.39–0.870.008
  • a RR and 95% CI were derived from incidence rate ratios, and Ps were derived from log-rank tests.

  • b 95% CI and Ps were derived from the Cox proportional hazards model adjusted for age (continuous), gender, and smoking (never, former, current) at randomization.